secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001703057-25-000024
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M
--------------------------------------------------------------

- Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.
- Total revenue $9.0M, up from $6.5M in Q3 2024.
- Appointed Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.
- Cumulative partner-initiated program starts with downstreams: 103; molecules in clinic: 18.
- Total available liquidity $680M ($523M cash/securities + $159M non-dilutive funding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/0001703057-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/abcl-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001703057-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer